These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 2922897

  • 1. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
    Rassweiler J, Rüther U, Bäuerle K, Bub P, Jipp P, Eisenberger F.
    Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
    Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M, AUO-AB 05/95.
    J Clin Oncol; 2005 Aug 01; 23(22):4963-74. PubMed ID: 15939920
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct 01; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 5. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    Ann Urol (Paris); 1993 Oct 01; 27(1):51-7. PubMed ID: 7682388
    [Abstract] [Full Text] [Related]

  • 6. [Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder].
    Campo B, Torelli T, Leidi GL, Corrada P, Bacchioni AM, Ordesi G, Zanitzer L.
    Arch Ital Urol Nefrol Androl; 1990 Jun 01; 62(2):237-42. PubMed ID: 2142807
    [Abstract] [Full Text] [Related]

  • 7. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M, Kotake T.
    Gan To Kagaku Ryoho; 1994 Oct 01; 21 Suppl 3():362-9. PubMed ID: 7986116
    [Abstract] [Full Text] [Related]

  • 8. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
    Klän R, Knispel H, Huland H.
    Urologe A; 1992 Jul 01; 31(4):247-50. PubMed ID: 1514213
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 01; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 10. [The M-VEC chemotherapy of advanced bladder tumors].
    Kumanov Kh, Ormanov I, Tsvetkov M, Donovski L.
    Khirurgiia (Sofiia); 1989 Sep 01; 42(6):39-45. PubMed ID: 2634800
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR, Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.
    Can J Urol; 2002 Oct 01; 9(5):1625-33. PubMed ID: 12431323
    [Abstract] [Full Text] [Related]

  • 12. Quality of life in patients with advanced bladder cancer treated by tumorectomy and systemic adjuvant polychemotherapy (M-VAC). Our experience in 14 cases.
    Valente R, Marini F, Signori GB, Martino F.
    Arch Esp Urol; 1989 Oct 01; 42(1):87-9. PubMed ID: 2712609
    [Abstract] [Full Text] [Related]

  • 13. Phase I-II pilot study on the efficacy and tolerability of neoadjuvant chemotherapy (Rescue M-VEC) and preoperative radiation therapy for infiltrating bladder cancer: results of an 18-month follow-up.
    Voce S, Montanari F, Arnone S, Dal Pozzo C, Suprani G, Cerullo G, Fornarola V.
    Arch Esp Urol; 1992 Jun 01; 45(5):491-8. PubMed ID: 1510485
    [Abstract] [Full Text] [Related]

  • 14. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N, Kosmas C, Skopelitis H, Dimitrakopoulos A, Kopterides P, Bougas D, Stravodimos K, Mitropoulos D, Alamanis C, Giannopoulos A.
    J Chemother; 2005 Aug 01; 17(4):441-8. PubMed ID: 16167525
    [Abstract] [Full Text] [Related]

  • 15. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A, Gotoh A, Hara I, Gohji K, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, Hamami G, Itani A.
    Gan To Kagaku Ryoho; 1990 Sep 01; 17(9):1909-15. PubMed ID: 2393308
    [Abstract] [Full Text] [Related]

  • 16. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    Tsai YS, Tzai TS, Chow NH.
    Urol Int; 2007 Sep 01; 79(3):210-6. PubMed ID: 17940352
    [Abstract] [Full Text] [Related]

  • 17. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
    González Enguita C, Caro Cebrián C, Roncalés Badal A, Gil Sanz MJ, Martínez Bengoechea J, Rioja Sanz LA.
    Arch Esp Urol; 1990 Sep 01; 43 Suppl 2():197-204. PubMed ID: 2096779
    [Abstract] [Full Text] [Related]

  • 18. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M.
    BJU Int; 2006 Jan 01; 97(1):42-7. PubMed ID: 16336326
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH, Hsieh RK, Chiou TJ, Chen KK, Chang LS, Chen PM.
    J Urol; 1996 Jan 01; 155(1):118-21. PubMed ID: 7490806
    [Abstract] [Full Text] [Related]

  • 20. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug 01; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.